T Cell Attack Discovery: New Insights for Cancer & Transplants | Nature Immunology

A newly discovered mechanism in how T cells – key players in the immune system – target and destroy cells could reshape our understanding of cancer immunology and improve the success of bone marrow transplantation. Researchers at Baylor College of Medicine (BCM) and the University of Michigan have identified a previously unrecognized way these immune cells attack, detailed in a study published in Nature Immunology.

The Immune System’s Hidden Attack Strategy

For decades, immunology has largely focused on T cells recognizing targets through their T cell receptors (TCRs) binding to specific antigens presented on the surface of other cells. This new research, led by Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at BCM, reveals that T cells can also kill target cells by directly engaging with ligands – molecules that bind to receptors – on the target cell surface, independent of the TCR. This alternative pathway involves a protein called Siglec-7, found on the surface of T cells.

“We’ve known for a long time that T cells can recognize and kill cancer cells, but the precise mechanisms have remained elusive,” explains Dr. Reddy. BCM News reports that this discovery challenges conventional wisdom and opens new avenues for therapeutic intervention. The study demonstrates that Siglec-7 interacts with specific sugar molecules (sialic acids) on target cells, triggering the T cell to release cytotoxic granules that kill the target.

How Does This Differ From Traditional T Cell Killing?

Traditionally, T cell-mediated killing relies on the TCR recognizing a specific antigen fragment presented by a molecule called MHC. This process is highly specific, ensuring that T cells only attack cells displaying the correct antigen. The newly discovered Siglec-7 pathway, however, is less specific. It relies on the presence of sialic acids, which are commonly found on the surface of many cells, including cancer cells. This broader recognition capability could be particularly useful in targeting cancers that don’t express easily identifiable antigens, or in situations where the antigen presentation machinery is impaired.

The research team, which included Drs. Arul Chinnaiyan and Marcin Cieslik from the University of Michigan Rogel Cancer Center, used a combination of biochemical assays, cell-based experiments, and mouse models to demonstrate the functionality of this Siglec-7 pathway. They found that blocking Siglec-7 reduced T cell-mediated killing of cancer cells in vitro and in vivo.

Implications for Bone Marrow Transplantation and Graft-versus-Host Disease

This discovery has significant implications for bone marrow transplantation, a procedure often used to treat blood cancers and other hematological disorders. A major complication of bone marrow transplantation is graft-versus-host disease (GVHD), where the donor’s immune cells attack the recipient’s tissues. The Siglec-7 pathway appears to play a role in GVHD, as blocking it reduced the severity of the disease in mouse models. Adopt A Scientist Cure Cancer details Dr. Reddy’s long-standing interest in the immunobiology of GVHD and his work to improve outcomes after hematopoietic cell transplantation.

“GVHD is a devastating complication of bone marrow transplantation,” says Dr. Reddy. “Understanding the mechanisms that drive GVHD is crucial for developing strategies to prevent or treat it.” By targeting Siglec-7, researchers may be able to selectively suppress the immune response that causes GVHD without compromising the beneficial anti-cancer effects of the transplanted immune cells.

Study Details and Limitations

The study involved a combination of in vitro experiments using human cells and in vivo experiments using mouse models. Researchers utilized CRISPR-Cas9 gene editing to knock out Siglec-7 in T cells and assess the impact on their cytotoxic activity. They also employed flow cytometry and mass spectrometry to identify the specific sialic acid ligands that bind to Siglec-7. While the findings are promising, it’s important to note that the study was conducted primarily in mice. Further research is needed to confirm these findings in humans and to determine the safety and efficacy of targeting Siglec-7 in clinical trials.

The researchers acknowledge that the precise role of Siglec-7 in different types of cancer and in various stages of GVHD remains to be fully elucidated. They also note that other factors likely contribute to T cell-mediated killing, and that the Siglec-7 pathway is likely just one piece of a complex puzzle.

What’s Next for Cancer Immunotherapy?

The discovery of the Siglec-7 pathway opens up new possibilities for developing more effective cancer immunotherapies. Researchers are now exploring ways to harness this pathway to enhance T cell-mediated killing of cancer cells. This could involve developing antibodies that block Siglec-7, or engineering T cells to express higher levels of Siglec-7. The Cancer Prevention and Research Institute of Texas (CPRIT) funded Dr. Reddy’s recruitment to Baylor, recognizing the potential of his research to transform cancer care.

However, it’s crucial to proceed with caution. Targeting Siglec-7 could have unintended consequences, as it may also affect the function of other immune cells. Careful preclinical studies and clinical trials will be necessary to ensure that any new therapies based on this pathway are safe and effective. The process of translating these findings into clinical applications will involve rigorous testing and evaluation, including Phase I, II, and III clinical trials to assess safety, efficacy, and optimal dosing.

Further research will also focus on identifying the specific types of cancer that are most likely to respond to therapies targeting Siglec-7. This will involve analyzing the expression of sialic acids on the surface of different cancer cells and correlating it with patient outcomes. The goal is to develop personalized immunotherapies that are tailored to the individual characteristics of each patient’s cancer.